Strides Pharma Science Limited
Quick Take
- • Trading at 18.3× trailing earnings (12.8× forward)
- • Strong ROE at 19.7%
- • Leveraged balance sheet (D/E 0.56)
- • Modest dividend yield of 0.42%
- • Operating margin 13.7% · Net margin 12.3%
- • Profit growth +57.40% YoY · Beta 0.39
Latest quarter · Jun 2026
| ₹ Cr | Jun 2026 | QoQ | YoY |
|---|---|---|---|
| Revenue | 1,265 | -4.38% | +6.30% |
| Operating Profit | 297 | +22.22% | +44.17% |
| Net Profit | 157 | +23.62% | +91.46% |
| EPS (₹) | 17.02 | +23.60% | +90.81% |
Shareholding Pattern
| Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 25.84% | 26.82% | 28.30% | 28.30% | 27.86% | 27.86% | 27.91% | 27.91% |
| FIIs▼0.29 | 30.08% | 28.48% | 28.32% | 28.02% | 28.51% | 29.52% | 28.68% | 28.39% |
| DIIs▲0.96 | 18.24% | 16.92% | 13.72% | 13.30% | 12.98% | 13.02% | 14.45% | 15.41% |
| Government | 0.00% | 0.00% | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public▼0.67 | 25.83% | 27.77% | 29.65% | 30.37% | 30.64% | 29.59% | 28.95% | 28.28% |
| No. of Shareholders | 96,008 | 1,14,237 | 95,125 | 92,889 | 91,206 | 85,589 | 86,616 | 94,850 |
* N
| Date | Party | Type | Side | Qty | Price |
|---|---|---|---|---|---|
| 28 Aug 26 | Arun Kumar Pillai | Block deal | BUY | 10,00,000 | ₹990.00 |
| 28 Aug 26 | Sbi Life Insurance Co.Ltd. | Block deal | SELL | 10,00,000 | ₹990.00 |
| 28 Aug 26 | Arun Kumar Pillai | Bulk deal | BUY | 10,00,000 | ₹990.00 |
| 28 Aug 26 | Sbi Life Insurance Co.Ltd. | Bulk deal | SELL | 10,00,000 | ₹990.00 |
| 31 Oct 25 | Graviton Research Capital Llp | Bulk deal | BUY | 5,78,738 | ₹937.22 |
| 31 Oct 25 | Graviton Research Capital Llp | Bulk deal | SELL | 5,78,738 | ₹938.69 |
About the company
From latest AR & concallStrides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally. The company offers generic finished dosage formulations in a range of dosages, such as tablets, hard capsules, sachets, liquids, nasal sprays, topical formulations, and controlled substances; and therapeutic products, including antivirals, antibiotics, NSAIDs, and allergy treatment. It also provides branded generics, prescription medicines, and over-the-counter products for infectious diseases, pain management, cardiology, and wellness; and prescription generics for anti-infectives, CNS, cardiovascular, gastroenterology, pain management, and specialty products. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
